Payment overview · 2025
General Payments
$422.46
21 reported records · 8 companies
Healthcare provider profile · identity verified
David John Gomeringer, DO
Allopathic & Osteopathic Physicians|Family Medicine · FORT MYERS, FL · NPI 1043236755
Verified facts
What the public records show
CMS Open Payments records show David John Gomeringer, DO received $422.46 in general payments during 2025 across 21 reported records.
GlaxoSmithKline, LLC. accounted for 26.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Paxlovid, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $111.28 | 26.3% | 6 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $73.72 | 17.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $67.40 | 15.9% | 4 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $41.27 | 9.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.22 | 9.3% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $39.19 | 9.3% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $27.71 | 6.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.67 | 5.4% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $422.46 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $111.28 | 6 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $73.72 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $52.00 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $41.27 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $39.22 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $39.19 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $27.71 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.67 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 18 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 60 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
60 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 309 | 93 |
| Atorvastatin Calcium | Atorvastatin Calcium | 279 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 279 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 237 | 86 |
| Lisinopril | Lisinopril | 232 | 69 |
| Prednisone | Prednisone | 221 | 137 |
| Hydrochlorothiazide | Hydrochlorothiazide | 194 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 192 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 182 | 66 |
| Famotidine | Famotidine | 173 | 60 |
| Losartan Potassium | Losartan Potassium | 159 | 49 |
| Alprazolam | Alprazolam | 144 | 30 |
| Azithromycin | Azithromycin | 135 | 95 |
| Meloxicam | Meloxicam | 134 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 37 |
| Clonazepam | Clonazepam | 113 | 26 |
| Omeprazole | Omeprazole | 110 | 37 |
| Allopurinol | Allopurinol | 109 | 30 |
| Gabapentin | Gabapentin | 104 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 93 | 18 |
| Metformin Hcl | Metformin Hcl | 91 | 36 |
| Irbesartan | Irbesartan | 90 | 29 |
| Doxycycline Hyclate | Doxycycline Hyclate | 89 | 54 |
| Ipratropium Bromide | Ipratropium Bromide | 88 | 53 |
| Ezetimibe | Ezetimibe | 85 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 84 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 79 | 28 |
| Trazodone Hcl | Trazodone Hcl | 74 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 24 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 66 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 64 | 14 |
| Cefdinir | Cefdinir | 61 | 48 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | 22 |
| Carvedilol | Carvedilol | 59 | 18 |
| Lorazepam | Lorazepam | 59 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 57 | 24 |
| Valsartan | Valsartan | 55 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 25 |
| Ibandronate Sodium | Ibandronate Sodium | 48 | 20 |
| Sertraline Hcl | Sertraline Hcl | 48 | 17 |
| Montelukast Sodium | Montelukast Sodium | 46 | 19 |
| Glipizide | Glipizide | 44 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 43 | 13 |
| Fluconazole | Fluconazole | 42 | 26 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 41 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 16 |
| Ozempic | Semaglutide | 36 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 17 |
| Simvastatin | Simvastatin | 34 | suppressed |
| Bumetanide | Bumetanide | 33 | 20 |
| Meclizine Hcl | Meclizine Hcl | 33 | 24 |
| Valacyclovir | Valacyclovir Hcl | 33 | 14 |
| Mupirocin | Mupirocin | 32 | 24 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 31 | 22 |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 30 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Eliquis | Apixaban | 27 | suppressed |
| Potassium Chloride | Potassium Chloride | 27 | 14 |
| Primidone | Primidone | 27 | suppressed |
| Digoxin | Digoxin | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Ketoconazole | Ketoconazole | 23 | 13 |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 12 |
| Telmisartan | Telmisartan | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 11 |
| Furosemide | Furosemide | 16 | suppressed |
| Trimethoprim | Trimethoprim | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 11 |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 13 |
| Finasteride | Finasteride | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $422.46 · 21 records | GlaxoSmithKline, LLC. | AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, ELIQUIS, INSPIRE, NEXLETOL, NURTEC ODT, PAXLOVID, TRELEGY ELLIPTA, TRINTELLIX, VOQUEZNA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error